investor.myriad.comInvestor relations | Myriad Genetics

Investor Relations Financial Reporting Filings and Reports SEC Filings Quarterly & Annual Reports Disclosures GAAP to Non-GAAP Reconciliation Resources Investor FAQs Email Alerts Subscription News Releases About Myriad Corporate information Corporate Governance Executive Team Myriad Milestones Latest events Events & Presentations Investor Day Contact Us NASDAQ: MYGN $25.36 1.72% DAY HIGH $25.50 YEAR HIGH $25.95 DAY LOW $24.91 YEAR LOW $13.82 05/14/2024 Search: NASDAQ: MYGN $25.36 1.72% Search: Investor Relations Financial Reporting Filings and Reports SEC Filings Quarterly & Annual Reports Disclosures GAAP to Non-GAAP Reconciliation Resources Investor FAQs Email Alerts Subscription News Releases About Myriad Corporate information Corporate Governance Executive Team Myriad Milestones Latest events Events & Presentations Investor Day Contact Us Myriad Genetics First Quarter 2024 Financial Earnings Tuesday, May 7, 2024 | 1:30pm PST / 4:30pm EST Watch the webcast Download presentation Events & Presentations 45th Annual Global Goldman Sachs Global Healthcare Conference 06/12/2024 | 12:20pm PDT / 3:20pm EDT To participate in the live conference call via telephone, please register hereLeerink Partners Healthcare Crossroads Conference 05/30/2024 | 8:00am PDT / 11:00am EDT To participate in the live conference call via telephone, please register hereWatch the webcast Piper Sandler Virtual Cancer Testing Day 05/21/2024 | 8:00am PDT / 11:00am EDT To participate in the live conference call via telephone, please register hereView all events Financial Reports and Filings Date Filing Title Downloads 05/14/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL 05/13/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL 05/13/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL 05/08/2024 10-Q Quarterly report which provides a continuing view of a company’s financial position RTF XLS PDF HTML XBRL 05/07/2024 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL 05/01/2024 SC 13G A statement of beneficial ownership of common stock by certain persons RTF XLS PDF HTML XBRL 04/25/2024 SC 13G A statement of beneficial ownership of common stock by certain persons RTF XLS PDF HTML XBRL 04/17/2024 ARS An annual report to security holders RTF XLS PDF HTML XBRL 04/17/2024 DEF 14A Official notification to shareholders of matters to be brought to a vote ("Proxy") RTF XLS PDF HTML XBRL 04/17/2024 DEFA14A Additional proxy soliciting materials - definitive RTF XLS PDF HTML XBRL View all filings Latest News Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA May 07, 2024 | Corporate | Financial Read more Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business May 07, 2024 | Products | Corporate Read more Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 Apr 30, 2024 | Corporate | Financial Read more View all news releases Our commitment to social responsibility At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives. Learn more about the actions we’re taking in ESG Read our ESG report As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report." — Paul Diaz President and CEO of Myriad Genetics Our commitment to social responsibility At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives. Learn more about the actions we’re taking in ESG Read our ESG report As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report." — Paul Diaz President and CEO of Myriad Genetics Payers Overview Investors Investor Relations Events & Presentations Investor Day News Email Alerts Subscription Myriad Genetics Blog Careers Joining the Team Terms of Use Myriad Genetics, Inc. Privacy Policy Notice of Privacy Practices Patents Language Assistance Cookie Preferences facebook linkedin x instagram youtube © 2024 Myriad Genetics,...